Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1848822 | 1.00 | NPC1 (0.60) | NPC1RAB9ACRHR1POLBBTK | |
| SCHEMBL1851117 | 0.91 | CRHR1 (0.58) | NPC1RAB9ACRHR1POLBBTK | |
| SCHEMBL1851119 | 0.91 | CRHR1 (0.58) | NPC1RAB9ACRHR1POLBBTK | |
| SCHEMBL3214247 | 0.84 | CRHR1 (0.54) | CRHR1BTKALDH1A1 | |
| SCHEMBL3214251 | 0.84 | CRHR1 (0.54) | CRHR1BTKALDH1A1 | |
| SCHEMBL457993 | 0.83 | NPC1 (0.84) | NPC1RAB9APOLBSMN1; SMN2GLA | |
| SCHEMBL23573548 | 0.82 | NPC1 (0.77) | NPC1RAB9APOLBSMN1; SMN2GLA | |
| SCHEMBL23573547 | 0.82 | NPC1 (0.77) | NPC1RAB9APOLBSMN1; SMN2GLA | |
| SCHEMBL1850057 | 0.81 | CRHR1 (0.67) | CRHR1 | |
| SCHEMBL1850059 | 0.81 | CRHR1 (0.67) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088105-A1 | Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists | NOVARTIS AG (CH) | 2014-03-27 | — | — | US | claimed |
| JP-2011529944-A | — | — | 2011-12-15 | — | — | JP | claimed |
| EP-2323970-A1 | CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2011-05-25 | — | — | EP | claimed |
| WO-2010015655-A1 | CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | claimed |
| US-20100035898-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | claimed |
| US-20140088105-A1 | Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists | NOVARTIS AG (CH) | 2014-03-27 | — | — | US | disclosed |
| US-20140088105-A1 | Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists | NOVARTIS AG (CH) | 2014-03-27 | — | — | US | disclosed |
| US-8614213-B2 | Cyclohexyl amide derivatives and their use as CRF-1 receptor antagonists | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | disclosed |
| US-8273900-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-25 | — | — | US | disclosed |
| US-8273900-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-25 | — | — | US | disclosed |
| US-8273900-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-25 | — | — | US | disclosed |
| US-20110152261-A1 | Organic compounds | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110152261-A1 | Organic compounds | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| EP-2323970-A1 | CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010015655-A1 | CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015655-A1 | CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035898-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| US-20100035898-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| US-20100035898-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035898-A1 | Organic compounds | CRH, CRHR1, CRHR2 | NPC1 784/4885RAB9A 3533/4885CRHR1 2/4885 |
| US-20110152261-A1 | Organic compounds | CRH, CRHR1, CRHR2 | NPC1 627/4885RAB9A 3527/4885CRHR1 2/4885 |
| US-20140088105-A1 | Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists | CRHR1, CRH, CRHR2 | NPC1 1205/4885RAB9A 2478/4885CRHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.